CD274 and cancer: For example, in advanced renal cell carcinoma (RCC) treated with nivolumab, the median overall survival (OS) was paradoxically longer in the PD-L1<1% population (27.4 months) compared to PD-L1≥1% group (21.8 months), challenging the pan-cancer predictive value (61).